Use of a ligand of the gamma-glutamyl transpeptldase of H. pylori (HPGGT) for the manufacture of a drug for the treatment of H. pylori infections, in particular gastro duodenal disorders, whereas the ligand significantly inhibits the HPGGT activity and abrogates the HPGGT dependent suppression of lymphocyte proliferation as assessed in a lymphocyte proliferation assay.